\nApproximately 5% of individuals have a mutation in a cancer predisposition gene, yet most are unaware.3 NCCN Guidelines\u00ae are a trusted source for hereditary cancer testing criteria, but their complexity and frequent updates may make them difficult for non-specialist clinicians and digital health tools to apply effectively. CARE addresses this gap by streamlining the hereditary cancer risk assessment process.<\/p>\n \n\u201cThe validation of CARE\u2019s accuracy reinforces what we\u2019ve experienced at HCA Healthcare\u2019s Sarah Cannon Cancer Network \u2013 that, in addition to being well received by our patients, CARE\u2019s assessment can reliably identify patients who need genetic services,\u201d said Dr. Dax Kurbegov, Vice President and Physician-In-Chief of Clinical Programs, HCA Healthcare\u2019s Sarah Cannon Cancer Network. \u201cWith demonstrated 99.5% accuracy in applying clinical guidelines, we can confidently scale hereditary cancer risk assessment across our community hospitals, ensuring more patients have access to potentially life-saving genetic insights.\u201d<\/p>\n \nThe Ambry CARE Program\u00ae leverages digital health solutions to enable health systems to stratify patients by cancer risks, driving personalized, proactive care. Its HIPAA-compliant application integrates with electronic health records and collects medical and family history directly from patients via a mobile-friendly assessment prior to in-person visits. The program weighs these data against guidelines to identify those who qualify for hereditary cancer testing and\/or increased breast cancer screening based on estimated breast cancer risk. This enables clinicians to make timely, evidenced-based medical decisions, while offering patients education and connection to third-party genetic counseling at no additional cost.<\/p>\n \nThe newly published study assessed CARE\u2019s accuracy by using the program to identify cases that met hereditary cancer testing criteria based on NCCN Guidelines for hereditary breast, ovarian, pancreatic, and prostate cancer, as well as for Lynch syndrome and familial adenomatous polyposis1,2. Researchers then compared CARE\u2019s results against those of certified genetic counselors reviewing the same cases, confirming its ability to accurately identify 398 out of 400 real-world patient cases.<\/p>\n \n\u201cCARE offers healthcare systems a quality, end-to-end solution that transforms how they identify the need for, implement, and scale genetic testing,\u201d added Tom Schoenherr, CEO of Ambry Genetics. \u201cBecause clinicians can trust CARE\u2019s comprehensive history collection and accurate risk assessment, they can feel confident expanding access to genetic services, improving outcomes for more patients, and making genetic testing a seamless part of their patient care and population health strategies.\u201d<\/p>\n \nABOUT AMBRY GENETICS\u00ae<\/p>\n \nAmbry Genetics translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.<\/p>\n \nABOUT TEMPUS<\/p>\n \nTempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world\u2019s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.<\/p>\n \nFORWARD LOOKING STATEMENTS<\/p>\n \nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus\u2019 industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Ambry Genetic\u2019s research and publications; the contributions of Ambry Genetic\u2019s research and findings to the larger scientific community and the use of its products and services to advance clinical care for patients are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoing to,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.<\/p>\n \nYou should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus\u2019 business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus\u2019 financial performance; the ability to attract and retain customers and partners; managing Tempus\u2019 growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus\u2019 intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled \u201cRisk Factors\u201d in Tempus\u2019 Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.<\/p>\n Contacts<\/b> <\/p>\n![](\"https:\/\/mms.businesswire.com\/media\/20250625826604\/en\/2508119\/22\/Ambry_logo_2025.jpg\"\/){kind=logo}
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20250625826604\/en\/2508119\/21\/Ambry_logo_2025.jpg\"\/){kind=logo}
<\/a><\/p>\n\n